EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Alicia T Widge iD, Amelia R Hofstetter iD, Katherine V Houser iD, Seemal F Awan, Grace L Chen, Maria C Burgos Florez iD, Nina M Berkowitz, Floreliz Mendoza, Cynthia S Hendel, LaSonji A Holman iD, Ingelise J Gordon iD, Preeti Apte iD und 32 weitere

Science Translational Medicine · 2023

DOI: 10.1126/scitranslmed.ade4790 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Alicia T Widge und 43 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: COVID-19, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the immune response on the conserved HA stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an HA stabilized stem ferritin nanoparticle vaccine (H1ssF) based on the H1 HA stem of A/New Caledonia/20/1999. Fifty-two healthy adults aged 18 to 70 years old enrolled to receive either 20 μg of H1ssF once ( n = 5) or 60 μg of H1ssF twice ( n = 47) with a prime-boost interval of 16 weeks. Thirty-five (74%) 60-μg dose participants received the boost, whereas 11 (23%) boost vaccinations were missed because of public health restrictions in the early stages of the COVID-19 pandemic. The primary objective of this trial was to evaluate the safety and tolerability of H1ssF, and the secondary objective was to evaluate antibody responses after vaccination. H1ssF was safe and well tolerated, with mild solicited local and systemic reactogenicity. The most common symptoms included pain or tenderness at the injection site ( n = 10, 19%), headache ( n = 10, 19%), and malaise ( n = 6, 12%). We found that H1ssF elicited cross-reactive neutralizing antibodies against the conserved HA stem of group 1 influenza viruses, despite previous H1 subtype head-specific immunity. These responses were durable, with neutralizing antibodies observed more than 1 year after vaccination. Our results support this platform as a step forward in the development of a universal influenza vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Influenza VaccinesInfluenza, HumanAdolescentAdultAgedHumansMiddle AgedYoung AdultAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesHemagglutinin Glycoproteins, Influenza VirusHemagglutininsPandemics

Substanzen

Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza Vaccines

Autor:innen und Institutionen

  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

ORCID-Profile: Alicia T Widge, Amelia R Hofstetter, Katherine V Houser, Maria C Burgos Florez, LaSonji A Holman, Ingelise J Gordon, Preeti Apte, Emily E Coates, Sandra Vazquez, Judy A Stein, Jason G Gall, Kevin Carlton, Rebecca A Gillespie, Adrian Creanga, Michelle C Crank, Sarah F Andrews, Mike Castro, Sandeep R Narpala, Bob C Lin, Victoria C Rosado, Raffael Nachbagauer, Peter Palese, Masaru Kanekiyo, Adrian B McDermott, Richard A Koup, Lesia K Dropulic, Barney S Graham

Förderung

  • NIAID NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Widge, A. T., Hofstetter, A. R., Houser, K. V., Awan, S. F., Chen, G. L., Burgos Florez, M. C., Berkowitz, N. M., Mendoza, F., Hendel, C. S., Holman, L. A., Gordon, I. J., Apte, P., Liang, C. J., Gaudinski, M. R., Coates, E. E., Strom, L., Wycuff, D., Vazquez, S., Stein, J. A., …, & VRC 321 study team (2023). An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ade4790

Vancouver

Widge AT, Hofstetter AR, Houser KV, Awan SF, Chen GL, Burgos Florez MC, et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.ade4790

BibTeX
@article{Widge2023,
  author = {Widge, Alicia T and Hofstetter, Amelia R and Houser, Katherine V and Awan, Seemal F and Chen, Grace L and Burgos Florez, Maria C and Berkowitz, Nina M and Mendoza, Floreliz and Hendel, Cynthia S and Holman, LaSonji A and Gordon, Ingelise J and Apte, Preeti and Liang, C Jason and Gaudinski, Martin R and Coates, Emily E and Strom, Larisa and Wycuff, Diane and Vazquez, Sandra and Stein, Judy A and Gall, Jason G and Adams, William C and Carlton, Kevin and Gillespie, Rebecca A and Creanga, Adrian and Crank, Michelle C and Andrews, Sarah F and Castro, Mike and Serebryannyy, Leonid A and Narpala, Sandeep R and Hatcher, Christian and Lin, Bob C and O'Connell, Sarah and Freyn, Alec W and Rosado, Victoria C and Nachbagauer, Raffael and Palese, Peter and Kanekiyo, Masaru and McDermott, Adrian B and Koup, Richard A and Dropulic, Lesia K and Graham, Barney S and Mascola, John R and Ledgerwood, Julie E and VRC 321 study team, VRC 321 study team},
  title = {An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults},
  journal = {Science Translational Medicine},
  year = {2023},
  doi = {10.1126/scitranslmed.ade4790}
}
Kostenlos starten →